NASDAQ:PRQR ProQR Therapeutics (PRQR) Stock Forecast, Price & News $1.85 +0.11 (+6.32%) (As of 06/1/2023 ET) Add Compare Share Share Today's Range$1.74▼$1.8650-Day Range$1.67▼$3.5952-Week Range$0.68▼$3.85Volume231,214 shsAverage Volume957,443 shsMarket Capitalization$149.52 millionP/E RatioN/ADividend YieldN/APrice Target$4.35 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media ProQR Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside135.1% Upside$4.35 Price TargetShort InterestHealthy2.45% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.11Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.25) to ($0.47) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.07 out of 5 starsMedical Sector1053rd out of 1,980 stocksPharmaceutical Preparations Industry517th out of 978 stocks 3.4 Analyst's Opinion Consensus RatingProQR Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.35, ProQR Therapeutics has a forecasted upside of 135.1% from its current price of $1.85.Amount of Analyst CoverageProQR Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.45% of the float of ProQR Therapeutics has been sold short.Short Interest Ratio / Days to CoverProQR Therapeutics has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ProQR Therapeutics has recently decreased by 33.50%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldProQR Therapeutics does not currently pay a dividend.Dividend GrowthProQR Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PRQR. Previous Next 3.4 News and Social Media Coverage News SentimentProQR Therapeutics has a news sentiment score of 1.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for ProQR Therapeutics this week, compared to 2 articles on an average week.MarketBeat Follows2 people have added ProQR Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ProQR Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.40% of the stock of ProQR Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 29.79% of the stock of ProQR Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for ProQR Therapeutics are expected to decrease in the coming year, from ($0.25) to ($0.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ProQR Therapeutics is -2.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ProQR Therapeutics is -2.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProQR Therapeutics has a P/B Ratio of 2.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About ProQR Therapeutics (NASDAQ:PRQR) StockProQR Therapeutics NV is a clinical stage biopharmaceutical company. It is engaged in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases, such as Leber congenital amaurosis 10, Usher syndrome type 2, and autosomal dominant retinitis pigmentosa. Its product pipeline includes Sepofarsen, Ultevursen, Axiomer technology, and RNA therapy. The company was founded by Daniel Anton de Boer, Gerard J. Platenburg, Henri A. Termeer, and Domenico Valerio on February 21, 2012 and is headquartered in Leiden, the Netherlands.Read More Receive PRQR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProQR Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address PRQR Stock News HeadlinesMay 30, 2023 | americanbankingnews.comAnalysts Offer Predictions for ProQR Therapeutics' FY2024 Earnings (NASDAQ:PRQR)May 24, 2023 | americanbankingnews.comProQR Therapeutics (NASDAQ:PRQR) to Post FY2023 Earnings of ($0.47) Per Share, Cantor Fitzgerald ForecastsJune 1, 2023 | Edge On The Street (Ad)Graphite Shortage Could Derail the $7 Trillion EV TransitionGraphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.May 23, 2023 | markets.businessinsider.comChardan Capital Remains a Hold on ProQR (PRQR)May 23, 2023 | americanbankingnews.comProQR Therapeutics (NASDAQ:PRQR) Lifted to "Hold" at StockNews.comMay 21, 2023 | americanbankingnews.comProQR Therapeutics (NASDAQ:PRQR) Price Target Cut to $4.50May 21, 2023 | americanbankingnews.comAnalysts Set Expectations for ProQR Therapeutics' Q2 2023 Earnings (NASDAQ:PRQR)May 20, 2023 | americanbankingnews.comProQR Therapeutics to Post Q4 2023 Earnings of $0.36 Per Share, HC Wainwright Forecasts (NASDAQ:PRQR)June 1, 2023 | Edge On The Street (Ad)The $193 Billion US-China War You Don't Know AboutThey're fighting for control of lithium – a key ingredient in EVs and clean energy technology. It's arguably the most important commodity of the 21st century. China owns 80% of global supply. But the US plans to grab a massive slice of the lithium market, which is forecasted to quadruple to $193 billion by 2028, according to Fortune Business Insights.May 18, 2023 | finance.yahoo.comProQR Therapeutics N.V. (NASDAQ:PRQR) Could Be Less Than A Year Away From ProfitabilityMay 17, 2023 | msn.comHC Wainwright & Co. Reiterates ProQR Therapeutics N.V (PRQR) Buy RecommendationMay 17, 2023 | msn.comJMP Securities Reiterates ProQR Therapeutics N.V (PRQR) Market Outperform RecommendationMay 17, 2023 | msn.comAnalyst Ratings for ProQR TherapeuticsMay 17, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Its Buy Rating for ProQR (PRQR)May 16, 2023 | msn.comRecap: ProQR Therapeutics Q1 EarningsMay 16, 2023 | finance.yahoo.comProQR Announces First Quarter 2023 Operating and Financial ResultsMay 13, 2023 | americanbankingnews.comProQR Therapeutics (NASDAQ:PRQR) Downgraded by StockNews.com to "Sell"May 12, 2023 | americanbankingnews.comProQR Therapeutics (NASDAQ:PRQR) Receives $4.45 Average Price Target from AnalystsMay 9, 2023 | finance.yahoo.comProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023April 20, 2023 | finance.yahoo.comProQR Announces Upcoming Investor Conferences in April and MayApril 18, 2023 | finance.yahoo.comProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023April 17, 2023 | americanbankingnews.comAnalysts Set ProQR Therapeutics (NASDAQ:PRQR) Price Target at $4.45April 10, 2023 | americanbankingnews.comProQR Therapeutics (NASDAQ:PRQR) PT Lowered to $2.25 at CitigroupApril 4, 2023 | americanbankingnews.comProQR Therapeutics to Post Q1 2023 Earnings of ($0.17) Per Share, HC Wainwright Forecasts (NASDAQ:PRQR)April 3, 2023 | americanbankingnews.comProQR Therapeutics (NASDAQ:PRQR) Lifted to Hold at StockNews.comMarch 31, 2023 | americanbankingnews.comAnalysts Offer Predictions for ProQR Therapeutics' Q4 2023 Earnings (NASDAQ:PRQR)March 31, 2023 | americanbankingnews.comProQR Therapeutics (NASDAQ:PRQR) Given New $5.00 Price Target at HC WainwrightSee More Headlines PRQR Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PRQR Company Calendar Last Earnings3/29/2023Today6/01/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PRQR CUSIPN/A CIK1612940 Webwww.proqr.com Phone(188) 166-7000FaxN/AEmployees1,504Year FoundedN/APrice Target and Rating Average Stock Price Forecast$4.35 High Stock Price Forecast$5.00 Low Stock Price Forecast$2.25 Forecasted Upside/Downside+135.1%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-68,600,000.00 Net Margins-1,707.31% Pretax Margin-1,711.09% Return on Equity-84.97% Return on Assets-37.05% Debt Debt-to-Equity Ratio0.07 Current Ratio8.25 Quick Ratio8.25 Sales & Book Value Annual Sales$4.25 million Price / Sales35.18 Cash FlowN/A Price / Cash FlowN/A Book Value$0.78 per share Price / Book2.37Miscellaneous Outstanding Shares80,820,000Free Float74,028,000Market Cap$149.52 million OptionableOptionable Beta0.05 Key ExecutivesDaniel Anton de BoerChief Executive OfficerSheila SponseleeVice President, Head-People & OperationsJurriaan DekkersChief Financial OfficerGerard J. PlatenburgChief Scientific OfficerAndrew MorrisVice President-Business DevelopmentKey CompetitorsEvofem BiosciencesNASDAQ:EVFMG1 TherapeuticsNASDAQ:GTHXGreenwich LifeSciencesNASDAQ:GLSIMilestone PharmaceuticalsNASDAQ:MISTOptiNoseNASDAQ:OPTNView All CompetitorsInstitutional OwnershipJPMorgan Chase & Co.Bought 220,778 shares on 5/18/2023Ownership: 0.275%Susquehanna International Group LLPBought 83,200 shares on 5/16/2023Ownership: 0.000%Jane Street Group LLCBought 37,121 shares on 5/16/2023Ownership: 0.069%Boothbay Fund Management LLCBought 5,460 shares on 5/15/2023Ownership: 0.118%Atom Investors LPSold 5,415 shares on 5/15/2023Ownership: 0.016%View All Institutional Transactions PRQR Stock - Frequently Asked Questions Should I buy or sell ProQR Therapeutics stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ProQR Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PRQR shares. View PRQR analyst ratings or view top-rated stocks. What is ProQR Therapeutics' stock price forecast for 2023? 5 Wall Street analysts have issued 12-month price targets for ProQR Therapeutics' stock. Their PRQR share price forecasts range from $2.25 to $5.00. On average, they anticipate the company's share price to reach $4.35 in the next twelve months. This suggests a possible upside of 135.1% from the stock's current price. View analysts price targets for PRQR or view top-rated stocks among Wall Street analysts. How have PRQR shares performed in 2023? ProQR Therapeutics' stock was trading at $3.70 at the start of the year. Since then, PRQR stock has decreased by 50.0% and is now trading at $1.85. View the best growth stocks for 2023 here. Are investors shorting ProQR Therapeutics? ProQR Therapeutics saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 1,370,000 shares, a decline of 33.5% from the April 30th total of 2,060,000 shares. Based on an average daily volume of 871,000 shares, the short-interest ratio is presently 1.6 days. Approximately 2.5% of the shares of the stock are short sold. View ProQR Therapeutics' Short Interest. When is ProQR Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our PRQR earnings forecast. How were ProQR Therapeutics' earnings last quarter? ProQR Therapeutics (NASDAQ:PRQR) released its quarterly earnings data on Wednesday, March, 29th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, beating analysts' consensus estimates of ($0.20) by $0.04. The biopharmaceutical company had revenue of $0.84 million for the quarter, compared to the consensus estimate of $1 million. ProQR Therapeutics had a negative trailing twelve-month return on equity of 84.97% and a negative net margin of 1,707.31%. What ETF holds ProQR Therapeutics' stock ? Direxion mRNA ETF holds 21,680 shares of PRQR stock, representing 1.52% of its portfolio. What other stocks do shareholders of ProQR Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other ProQR Therapeutics investors own include (BIOA) (BIOA), Galapagos (GLPG), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), uniQure (QURE), Viking Therapeutics (VKTX) and Aldeyra Therapeutics (ALDX). What is ProQR Therapeutics' stock symbol? ProQR Therapeutics trades on the NASDAQ under the ticker symbol "PRQR." Who are ProQR Therapeutics' major shareholders? ProQR Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include EcoR1 Capital LLC (3.59%), Two Sigma Investments LP (0.52%), Two Sigma Advisers LP (0.46%), JPMorgan Chase & Co. (0.28%), HRT Financial LP (0.21%) and Bank of America Corp DE (0.19%). How do I buy shares of ProQR Therapeutics? Shares of PRQR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is ProQR Therapeutics' stock price today? One share of PRQR stock can currently be purchased for approximately $1.85. How much money does ProQR Therapeutics make? ProQR Therapeutics (NASDAQ:PRQR) has a market capitalization of $149.52 million and generates $4.25 million in revenue each year. The biopharmaceutical company earns $-68,600,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis. How many employees does ProQR Therapeutics have? The company employs 1,504 workers across the globe. How can I contact ProQR Therapeutics? ProQR Therapeutics' mailing address is Zernikedreef 9, Leiden P7, 2333 CK. The official website for the company is www.proqr.com. The biopharmaceutical company can be reached via phone at (188) 166-7000 or via email at ir@proqr.com. This page (NASDAQ:PRQR) was last updated on 6/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProQR Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.